home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.100 -0.030 (-0.73%)

Streaming Delayed Price Updated: 2:51 PM EST, Feb 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

October 26, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

October 09, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Recap: Can Fite Biofarma Q1 Earnings ↗

June 01, 2023

Via Benzinga

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

September 27, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

September 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

August 31, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

August 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

August 18, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

July 17, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

July 07, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

June 29, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

June 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

June 02, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

June 01, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

May 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

May 15, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

May 09, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 05, 2023

Via Benzinga

Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding

May 02, 2023

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

Via MarketBeat

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 02, 2023

Via Benzinga

Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

May 02, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization

April 24, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 13, 2023

It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 11, 2023

Via Benzinga

Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment

April 10, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know ↗

March 30, 2023

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months...

Via Benzinga

Can-Fite Reports 2022 Financial Results & Provides Clinical Update

March 30, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson

March 16, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting

March 13, 2023

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com